Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of APNmAb005 in Healthy Subjects
NCT05344989Phase 1Unknown
- Sponsor
- APRINOIA Therapeutics
- Start
- May 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APNmAb005 in Alzheimer's disease (AD) and tauopathy (5 cohorts), sponsored by APRINOIA Therapeutics. Primary endpoints: Number of subjects with Adverse Events at Day 70, Number of subjects with Treatment-emergent Adverse Events at Day 70 and 5 more. Status: unknown.
02
Drugs
APNmAb005
03
Conditions
Alzheimer's disease (AD)tauopathy
Beyond the preview
Go deeper on NCT05344989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344989.